AAAAAA

   
Results: 1-7 |
Results: 7
CAFFEINE PHARMACOKINETICS (PK) IN PREMATURE-INFANTS WITH APNEA OF PREMATURITY (AOP)
Authors: LEFF R ERENBERG A WYNNE B LUDDEN T
Citation: R. Leff et al., CAFFEINE PHARMACOKINETICS (PK) IN PREMATURE-INFANTS WITH APNEA OF PREMATURITY (AOP), Journal of investigative medicine, 46(1), 1998, pp. 137-137
RESULTS OF THE FIRST DOUBLE-BLIND PLACEBO (PL) CONTROLLED-STUDY OF CAFFEINE CITRATE (CC) FOR THE TREATMENT OF APNEA OF PREMATURITY (AOP)
Authors: ERENBERG A LEFF R WYNNE B LUDDEN T
Citation: A. Erenberg et al., RESULTS OF THE FIRST DOUBLE-BLIND PLACEBO (PL) CONTROLLED-STUDY OF CAFFEINE CITRATE (CC) FOR THE TREATMENT OF APNEA OF PREMATURITY (AOP), Pediatrics (Evanston), 102(3), 1998, pp. 756-757
NONLINEAR MIXED EFFECTS MODELING OF SINGLE-DOSE AND MULTIPLE-DOSE DATA FOR AN IMMEDIATE-RELEASE (IR) AND A CONTROLLED-RELEASE (CR) DOSAGE FORM OF ALPRAZOLAM
Authors: HOSSAIN M WRIGHT E BAWEJA R LUDDEN T MILLER R
Citation: M. Hossain et al., NONLINEAR MIXED EFFECTS MODELING OF SINGLE-DOSE AND MULTIPLE-DOSE DATA FOR AN IMMEDIATE-RELEASE (IR) AND A CONTROLLED-RELEASE (CR) DOSAGE FORM OF ALPRAZOLAM, Pharmaceutical research, 14(3), 1997, pp. 309-315
POPULATION PHARMACOKINETICS (PK) PHARMACODYNAMICS (PD) OF MINOXIDIL (MNX)
Authors: FADIRAN EO MILLER R LUDDEN T KARKOWSKY A PAREKH A FERRY J
Citation: Eo. Fadiran et al., POPULATION PHARMACOKINETICS (PK) PHARMACODYNAMICS (PD) OF MINOXIDIL (MNX), Clinical pharmacology and therapeutics, 61(2), 1997, pp. 46-46
ENHANCE POPULATION PHARMACOKINETIC (PPK) KNOWLEDGE FOR A SPARSELY SAMPLED POPULATION BY BORROWING STRENGTH OF INFORMATION FROM DIFFERENT POPULATIONS
Authors: WANG D ZHU GR LUDDEN T
Citation: D. Wang et al., ENHANCE POPULATION PHARMACOKINETIC (PPK) KNOWLEDGE FOR A SPARSELY SAMPLED POPULATION BY BORROWING STRENGTH OF INFORMATION FROM DIFFERENT POPULATIONS, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 68-68
OPPORTUNITIES FOR INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN RATIONAL DRUG DEVELOPMENT
Authors: PECK CC BARR WH BENET LZ COLLINS J DESJARDINS RE FURST DE HARTER JG LEVY G LUDDEN T RODMAN JH SANATHANAN L SCHENTAG JJ SHAH VP SHEINER LB SKELLY JP STANSKI DR TEMPLE RJ VISWANATHAN CT WEISSINGER J YACOBI A
Citation: Cc. Peck et al., OPPORTUNITIES FOR INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN RATIONAL DRUG DEVELOPMENT, Journal of clinical pharmacology, 34(2), 1994, pp. 111-119
BIAS (B) AND EFFICIENCY (EFF) EFFECTS OF CORRELATION (CORR) BETWEEN PHARMACOKINETICS (PK) AND PHARMACODYMAMICS (PD) IN POST-HOC CONCENTRATION-EFFECT (CE) ANALYSES OF PARALLEL DOSE-RESPONSE TRIALS
Authors: PECK C LUDDEN T
Citation: C. Peck et T. Ludden, BIAS (B) AND EFFICIENCY (EFF) EFFECTS OF CORRELATION (CORR) BETWEEN PHARMACOKINETICS (PK) AND PHARMACODYMAMICS (PD) IN POST-HOC CONCENTRATION-EFFECT (CE) ANALYSES OF PARALLEL DOSE-RESPONSE TRIALS, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 163-163
Risultati: 1-7 |